RxDoctor Payments Data

Melissa Miles

Psychiatric/Mental Health · Oldsmar, FLNPI 1912789918

Payments from drug & device makers

$9,228in general payments, 2019–2025

Across 433 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Vanda Pharmaceuticals Inc.$863
  • Neurocrine Biosciences, Inc.$815
  • Johnson & Johnson$784
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$732
  • plus $3K from 11 others

What the payments were for

  • Food & beverage$9,228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,228 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$37,031
Medicare patients
89
Services billed
506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine15$115,627
IngrezzaValbenazine Tosylate12$97,709
VraylarCariprazine Hcl58$86,410
CaplytaLumateperone Tosylate28$45,158
RexultiBrexpiprazole22$33,048
TrintellixVortioxetine Hydrobromide28$18,314
Aripiprazole165$6,005
Duloxetine Hcl266$5,056
Olanzapine86$3,969
Hydroxyzine Hcl217$3,586
Buspirone Hcl274$3,548
Quetiapine Fumarate224$3,072
Sertraline Hcl237$2,809
Trazodone Hcl233$2,278
Lamotrigine205$2,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,075$115,62715 claims
Neurocrine Biosciences, Inc.Ingrezza$815$97,70912 claims
AbbVieVraylar$1,833$86,41058 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$732$45,15828 claims
Otsuka America Pharmaceutical, Inc.Rexulti$520$33,04822 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$610$18,31428 claims
Almatica Pharma LLCSertraline Hcl$78$2,809237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Oldsmar

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →